论文部分内容阅读
采用酶联免疫吸附法（ELISA）检测了177例癌症（其中食管瘤2例、胃癌12例、肠癌47例、肝癌71例、胆管癌1例、胰腺癌4例、肺癌26例、乳腺癌9例、卵巢癌2例、子宫癌2例、鼻咽癌1例）患言血清可溶性肿瘤坏死因子受体I（sTNFRI）水平。结果显示病人血清中sTNFRI浓度（12904±45．58U／ml）显著高于正常对照组（51．64±26.67U／ml）．P＜0．05，而在各种癌症患者中，肝癌病人的sTNFRI水平为最高（223.07±177．16U／ml）。其结果对了解肿瘤病人的异常免疫状态以及sTNFRI检测的临床价值具有重要意义。
177 cancers were detected by enzyme-linked immunosorbent assay (ELISA) (including 2 cases of esophageal cancer, 12 cases of gastric cancer, 47 cases of intestinal cancer, 71 cases of hepatocellular carcinoma, 1 case of cholangiocarcinoma, 4 cases of pancreatic cancer, 26 cases of lung cancer, and breast cancer). Nine cases, 2 cases of ovarian cancer, 2 cases of uterine cancer, and 1 case of nasopharyngeal cancer affected serum levels of soluble tumor necrosis factor receptor I (sTNFRI). The results showed that the serum sTNFRI concentration (12904 ± 45.58U/ml) was significantly higher than the normal control group (51.64 ± 26.67U/ml). P<0.05, while the sTNFRI level was highest in patients with various types of cancer (223.07±177.16 U/ml). The results are important for understanding the abnormal immune status of tumor patients and the clinical value of sTNFRI detection.